Trastuzumab (Herceptin) is a molecular targeted drug of ERBB2-positive metastatic/advanced breast cancer and gastric cancer (Bang et al., 2010; Loibl and Gianni, 2017). The gene discussed is ERBB2; the disease is breast carcinoma.